Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Sphingotec GmbH, Hennigsdorf, Germany.
J Card Fail. 2017 Mar;23(3):231-239. doi: 10.1016/j.cardfail.2016.09.007. Epub 2016 Sep 20.
Proenkephalin (pro-ENK) has emerged as a novel biomarker associated with both renal function and cardiac function. However, its clinical and prognostic value have not been well evaluated in symptomatic patients with heart failure.
The association between pro-ENK and markers of renal function was evaluated in 95 patients with chronic heart failure who underwent renal hemodynamic measurements, including renal blood flow (RBF) and glomerular filtration rate (GFR) with the use of I-Hippuran and I-iothalamate clearances, respectively. The association between pro-ENK and clinical outcome in acute heart failure was assessed in another 1589 patients. Pro-ENK was strongly correlated with both RBF (P < .001) and GFR (P < .001), but not with renal tubular markers. In the acute heart failure cohort, pro-ENK was a predictor of death through 180 days, heart failure rehospitalization through 60 days, and death or cardiovascular or renal rehospitalization through day 60 in univariable analyses, but its predictive value was lost in a multivariable model when other renal markers were entered in the model.
In patients with chronic and acute heart failure, pro-ENK is strongly associated with glomerular function, but not with tubular damage. Pro-ENK provides limited prognostic information in patients with acute heart failure on top of established renal markers.
前啡肽(pro-ENK)作为与肾功能和心功能均相关的新型生物标志物而备受关注。然而,在有症状的心衰患者中,其临床和预后价值尚未得到充分评估。
本研究纳入 95 例慢性心衰患者,分别采用碘海醇和碘他拉酸盐清除率评估肾血流(RBF)和肾小球滤过率(GFR),并检测其 pro-ENK 与肾功能标志物的相关性。另外,本研究还纳入了 1589 例急性心衰患者,评估 pro-ENK 与临床结局的相关性。Pro-ENK 与 RBF(P < .001)和 GFR(P < .001)均呈显著正相关,但与肾小管标志物无关。在急性心衰患者队列中,pro-ENK 是 180 天内死亡、60 天内心衰再入院、60 天内心血管或肾脏再入院的单变量分析预测因子,但在多变量模型中,当其他肾功能标志物进入模型后,其预测价值丧失。
在慢性和急性心衰患者中,pro-ENK 与肾小球功能密切相关,但与肾小管损伤无关。在急性心衰患者中,除了已有的肾功能标志物外,pro-ENK 提供的预后信息有限。